Summary: For the first three months of 2009 the Pharmexa Group generated
revenues of DKK 4.1 million and a net loss of DKK 12.7 million. Research and
development costs totalled DKK 10.5 million. On May 5, 2009 Pharmexa's
shareholders approved the proposed combination with the Norwegian biotech
company Affitech AS. The enlarged company expects a net loss for 2009 of DKK
45-50 million. Pharmexa's previously announced expectations was a net loss in
2009 of approximately DKK 25 million, based on Pharmexa as a standalone
company.
